SavedAdd your journal

Journals / Ankara Üniversitesi Veteriner Fakültesi Dergisi / 2020 / Cilt: 67 - Sayı: 1

Pharmacotherapy of canine atopic dermatitis - current state and new trends

Wolfgang BÄUMER
Pages
107–111
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Apart from these substance classes, antihistamines, essential fatty acids and lipid substitution will be discussed as add-on treatments.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:This review offers a concise overview of current treatment options for canine atopic dermatitis and provide an outline of two promising new treatment options (phosphodiesterase 4 and histamine H4 receptor inhibitors).
📊
Key Findings & Data:Ciclosporin was introduced more than 15 years ago and is also a main pharmacological treatment option.
💡
Conclusion & Impact:Apart from these substance classes, antihistamines, essential fatty acids and lipid substitution will be discussed as add-on treatments.
🔬Design:Review & Systematic Survey
📍Scope:2013 Verileri
⚙️Variables:Domain Parameters

Abstract

This review offers a concise overview of current treatment options for canine atopic dermatitis and provide an outline of two promising new treatment options (phosphodiesterase 4 and histamine H4 receptor inhibitors). Glucocorticoids have been one of the first successful treatment options and are still part of the treatment regime. Ciclosporin was introduced more than 15 years ago and is also a main pharmacological treatment option. In 2013, the Janus kinase inhibitor oclacitinib was introduced as a first in class, which is then followed by the anti-canine IL-31 antibody lokivetmab in 2016. Thus, exciting new treatment options have found their way into clinical practice. Apart from these substance classes, antihistamines, essential fatty acids and lipid substitution will be discussed as add-on treatments.

🔖

Cite This Article

BÄUMER, W. (2022). Pharmacotherapy of canine atopic dermatitis - current state and new trends. Ankara Üniversitesi Veteriner Fakültesi Dergisi, Cilt: 67 - Sayı: 1, 107–111. https://ajindex.com/articles/444472

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Bäumer W, Hoppmann J, Rundfeldt C, et al (2007): Highly selective phosphodiesterase 4 inhibitors for the treatment of allergic skin diseases and psoriasis. Inflamm Allergy Drug Targets, 6, 17-26
  2. Bäumer W, Kietzmann M (2007): Effects of cyclosporin A and cilomilast on activated canine, murine and human keratinocytes. Vet Dermatol, 18, 107-114
  3. Bäumer W, Kietzmann M (2009): Pharmakotherapie der atopischen Dermatitis – aktueller Stand und neue Entwicklungen Einleitung. Tierärztliche Praxis, 38, (Suppl 1), 45-49
  4. Bäumer W, Stahl J, Sander K, et al (2011): Lack of preventing effect of systemically and topically administered histamine H(1) or H(4) receptor antagonists in a dog model of acute atopic dermatitis. Exp Dermatol, 20, 577-581
  5. Bensignor E, Morgan DM, Nuttall T (2008): Efficacy of an essential fatty acid-enriched diet in managing canine atopic dermatitis: a randomized, single-blinded, cross-over study. Vet Dermatol, 19, 156-162
  6. Bizikova P, Papich MG, Olivry T (2008): Hydroxyzine and cetirizine pharmacokinetics and pharmacodynamics after oral and intravenous administration of hydroxyzine to healthy dogs. Vet Dermatol, 19, 348-357
  7. Callender VD, Alexis AF, Stein Gold LF, et al (2019): Efficacy and Safety of Crisaborole Ointment, 2%, for the Treatment of Mild-to-Moderate Atopic Dermatitis Across Racial and Ethnic Groups. Am J Clin Dermatol, 20, 711-723
  8. Chermprapai S, Broere F, Gooris G, et al (2018): Altered lipid properties of the stratum corneum in Canine Atopic Dermatitis. Biochim Biophys Acta Biomembr, 1860, 526-533
  9. Cosgrove SB, Wren JA, Cleaver DM, et al (2013): A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis. Vet Dermatol, 24, 587-597
  10. Cosgrove SB, Wren JA, Cleaver DM, et al (2013): Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Vet Dermatol, 24, 479-e114
  11. Ehling S, Bäumer W, Papich MG (2019): Diphenhydramine pharmacokinetics after oral and intravenous administration of diphenhydramine and oral administration of dimenhydrinate to healthy dogs, and pharmacodynamic effect on histamine-induced wheal formation: a pilot study. Vet Dermatol, 30, 91-e24
  12. Ferrer L, Alberola J, Queralt M, et al (1999): Clinical anti-inflammatory efficacy of arofylline, a new selective phosphodiesterase-4 inhibitor, in dogs with